
Kilitch Drugs (India) Ltd. (KILITCH) Drugs Share Price rises 7.75% near lifetime high
Updated: 6 Oct 2026 • 9:25 am
Posted by:

Kilitch Drugs Share Price is Rs 251.60, up 7.75% from the previous close, and trading close to its lifetime high as of 06 October 2026 at 9:24:18 AM IST. Kilitch Drugs (India) Ltd. carries a market capitalisation of Rs 755.34 crore, placing the stock firmly in focus on Univest as the latest price action keeps it near the top of its range.
The move was visible in the first part of the trading day, with Kilitch Drugs Share Price opening at Rs 243.90, touching Rs 252.00 and moving between Rs 238.15 and Rs 252.00. According to latest Univest data, the price event is confirmed, but the data does not establish a company-specific catalyst. For readers following Kilitch Drugs Share Price Today, the key takeaway is simple: the stock is trading close to its peak zone while the market cap remains below Rs 1,000 crore.
Kilitch Drugs Share Price Today: Price Action Analysis
For Kilitch Drugs Share News and Kilitch Drugs Stock News readers, the event matters because it combines a sharp day move with a position near the lifetime high area. Univest tracks such moves because they often draw attention to the underlying stock story, valuation context and sector comparison. In this case, the numbers point to a stock that is already well above its longer-range trading averages and is now being watched for follow-through in price behaviour.
| Metric | Value |
|---|---|
| Current Price | Rs 251.6 |
| Previous Close | Rs 233.5 |
| Today's Move | +Rs 18.1 (+7.75%) |
| Open | Rs 243.9 |
| High | Rs 252 |
| Low | Rs 238.15 |
| Market Capitalisation | Rs 755.34 crore |
Kilitch Drugs (India) Ltd. (KILITCH) traded at Rs 251.6 versus the previous close of Rs 233.5, a rise of 7.75%. The stock opened at Rs 243.9, reached a high of Rs 252 and touched a low of Rs 238.15.
Kilitch Drugs Share Price Today was Rs 251.60 versus the previous close of Rs 233.50, a gain of Rs 18.10 or 7.75%. The stock opened at Rs 243.90, rose to Rs 252.00 and held above the previous close through the latest update. The day low of Rs 238.15 stayed above the prior close for part of the move, while the latest price remained just under the day high. This is the core Kilitch Drugs Share Price Update for the morning session: a strong upward move, a tight position near the top of the day’s range and a level that keeps the stock close to its lifetime high area.
For Kilitch Drugs Stock Performance tracking, the important point is that the current move is not isolated from the broader context. Kilitch Drugs Share Price Today is also sitting well above the 50-day average of Rs 193.64 and the 200-day average of Rs 175.56. That places the stock in a materially stronger position than it had at those longer markers, which is why the latest Kilitch Drugs News Today remains on watch lists across Share Market Today screens and Stocks in News coverage. The latest Univest data confirms the price event, and that is what makes the Kilitch Drugs Share Price story relevant right now.
Kilitch Drugs (India) Ltd. (KILITCH) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 755.34 crore |
| P/E Ratio | 27.16x |
| P/B Ratio | 2.9x |
| ROE | 12.26% |
| ROCE | 14.5% |
| EPS | Rs 8.6 |
| Book Value Per Share | Rs 80.45 |
| Dividend Yield | 0% |
Kilitch Drugs (India) Ltd. (KILITCH) fundamental metrics show P/E 27.16x, P/B 2.9x, ROE 12.26%, ROCE 14.5%. These figures provide context only and are not a buy or sell signal.
Kilitch Drugs (India) Ltd. has a market capitalisation of Rs 755.34 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 27.16x, P/B at 2.9x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.26% and ROCE of 14.5%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 8.6, book value per share of Rs 80.45, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.79x, median ROE of 11.73%, median ROCE of 13.63%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 27.16x |
| Benchmark Median P/E | 31.79x |
| Benchmark Average P/E | 47.98x |
| Benchmark P/E Range | 3.58x to 668.09x |
| Company P/B Ratio | 2.9x |
| Benchmark Median P/B | 2.9x |
| Company ROE | 12.26% |
| Benchmark Median ROE | 11.73% |
| Company ROCE | 14.5% |
| Benchmark Median ROCE | 13.63% |
| Company Market Capitalisation | Rs 755.34 crore |
| Benchmark Median Market Cap | Rs 812.84 crore |
Kilitch Drugs (India) Ltd. (KILITCH) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Kilitch Drugs (India) Ltd. (KILITCH) has a P/E ratio of 27.16x, which is below the benchmark median of 31.79x, a difference of -14.56%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Kilitch Drugs (India) Ltd. (KILITCH) has a ROE of 12.26%, which is above the benchmark median of 11.73%, a difference of +4.52%. Kilitch Drugs (India) Ltd. (KILITCH) has a ROCE of 14.5%, which is above the benchmark median of 13.63%, a difference of +6.38%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,34,279.63 | 35.35 | 4.94 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,46,737.12 | 83.61 | 13.85 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,81,129.27 | 82.93 | 20.15 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,14,239.13 | 25.16 | 4.21 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,08,808.05 | 31.97 | 3.07 | 11.83 | 16 |
Kilitch Drugs (India) Ltd. (KILITCH) has a P/E ratio of 27.16x compared with the displayed peer median of 35.35x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.26% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 14.5% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Kilitch Drugs (India) Ltd. (KILITCH) has a market capitalisation of Rs 755.34 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Kilitch Drugs
- Kilitch Drugs Share Price is Rs 251.60, up 7.75% from the previous close.
- The stock is trading close to its lifetime high area, with a latest high of Rs 252.00.
- Kilitch Drugs Share Price Today stands above both the 50-day average and the 200-day average.
- P/E of 27.16 is below the same-industry median of 31.79.
- ROE of 12.26% and ROCE of 14.5% are both above the same-industry medians.
About Kilitch Drugs
Kilitch Drugs (India) Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is listed on NSE and BSE as KILITCH. For readers checking Kilitch Drugs Company News, the current market view is shaped by the latest share price, valuation ratios, profitability metrics and the company’s position within the same-industry benchmark set used by Univest.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What is Kilitch Drugs Share Price today?
Ans. Kilitch Drugs Share Price is Rs 251.60 in the latest update. It is up 7.75% from the previous close of Rs 233.50 and remains near its lifetime high area.
Why is Kilitch Drugs Share Price in focus today?
Ans. Kilitch Drugs Share Price is in focus because it moved to Rs 251.60 after a 7.75% rise. The stock also touched Rs 252.00 during the session, keeping it near peak levels.
What was the previous close for Kilitch Drugs Share Price?
Ans. The previous close for Kilitch Drugs Share Price was Rs 233.50. The latest price of Rs 251.60 means the stock is trading Rs 18.10 above that level in the current update.
How does Kilitch Drugs Share Price compare with the 50-day average?
Ans. Kilitch Drugs Share Price is above its 50-day average of Rs 193.64. That comparison places the current price well above its longer-range reference point and is useful for stock analysis.
How does Kilitch Drugs Share Price compare with the 200-day average?
Ans. Kilitch Drugs Share Price is above its 200-day average of Rs 175.56. The gap shows that the latest price is materially higher than the long-term average level used in market review.
What does Kilitch Drugs Fundamental Analysis show?
Ans. Kilitch Drugs Fundamental Analysis shows a market cap of Rs 755.34 crore, P/E of 27.16, P/B of 2.9, ROE of 12.26%, ROCE of 14.5%, EPS of 8.6 and book value of Rs 80.45.
How does Kilitch Drugs compare with the healthcare industry benchmark?
Ans. In the same-industry benchmark, Kilitch Drugs trades below the P/E median of 31.79 and matches the P/B median of 2.9. Its ROE and ROCE are both above the benchmark medians.
What should readers track in Kilitch Drugs Share Price next?
Ans. Readers should track whether Kilitch Drugs Share Price stays near the current range, how it trades around Rs 252.00, and how its valuation compares with the same-industry peer set on Univest.
Track Kilitch Drugs Share Price on Univest
Use Kilitch Drugs (India) Ltd. (KILITCH) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Univest lets users track Kilitch Drugs Share Price, Kilitch Drugs Share Price Today, Kilitch Drugs Stock News and Kilitch Drugs Latest News in one place. You can also follow market cap, P/E ratio, P/B ratio, ROE, ROCE, EPS, book value, dividend yield, sector comparison and peer comparison on the same stock page.
Recent Articles

Honasa Consumer (HONASA) Share Price Rises 5.38% as HONASA Traded Higher Today
6 October 2026

SBC Exports (SBC) Ltd 52 Week High Streak: Second Straight Session
6 October 2026

Jaykay Enterprises Ltd. (JAYKAY) Share Price Rise Streak Continues for Second Straight Session
6 October 2026

Veerhealth Care Ltd. (VEERHEALTH) Care Share Price Near 52-Week High After 2.39% Rise
6 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Honasa Consumer (HONASA) Share Price Rises 5.38% as HONASA Traded Higher Today
SBC Exports (SBC) Ltd 52 Week High Streak: Second Straight Session
Jaykay Enterprises Ltd. (JAYKAY) Share Price Rise Streak Continues for Second Straight Session
Veerhealth Care Ltd. (VEERHEALTH) Care Share Price Near 52-Week High After 2.39% Rise
SMC Global Securities Ltd. (SMCGLOBAL) Share Price Hits Fresh 52-Week High on NSE
Popular this week
MONEYVIEW (MONEYVIEW) Share Price hits fresh 52-week low at Rs 49.48; stock trades at Rs 49.83

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





